TATVA

- 30th Annual General Meeting (AGM) scheduled for Friday, 25 September 2026, at 04:00 p.m. (IST). - Record date for determining eligibility for the final dividend for Financial Year 2025-26 is Friday, 11 September 2026. - Register of Members and Share Transfer Books will remain closed from Saturday, 12 September 2026, to Friday, 25 September 2026. - Cut-off date for e-voting on AGM resolutions is Friday, 18 September 2026.

- Submission of the Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - Environment: Progressed on carbon intensity reduction, secured 3.2 MW Wind-Solar hybrid power, and planned a 155 kW rooftop solar plant to support a 20% GHG intensity reduction goal by 2030. - Social: Implemented CSR initiatives focusing on education, rural development, environmental sustainability, and healthcare. Surpassed EHS training target with an average of 26 hours per employee. - Governance: Reported no instances of corruption or bribery, demonstrating commitment to ethical conduct and corporate integrity.

- Mr. Ajay Rawat, Assistant Vice President – Research and Development (Senior Management Personnel) of Tatva Chintan Pharma Chem Limited, has resigned. - The resignation was submitted on August 14, 2026, accepted on August 19, 2026, and will be effective from the close of business hours on November 13, 2026. - The reason for resignation is to pursue career opportunities outside the Company.

- Intimation regarding final dividend of ₹2.00/- (20%) per equity share for FY 2025-26. - Details provided on Tax Deduction at Source (TDS) as per Income-tax Act, 2025. - Shareholders are advised to update PAN, Aadhaar, and bank details by September 10, 2026, for accurate TDS deduction.

New Filing detected. See link for details.

New Filing detected. See link for details.

- Tatva Chintan Pharma Chem Limited has scheduled a virtual one-to-one meeting with Mahindra Manulife Investment Management Private Limited on August 06, 2026. - Only publicly available information will be discussed, with no confidential data to be shared.

- Concall Schedule - Concall Date: 06 August 2026 - Concall Type: One to One Meeting - Concall Mode: Virtual Meeting - Attending Institution: ChrysCapital Associates LLP

- Meeting Schedule - Meeting Date: 31 July 2026 - Participants: Motilal Oswal AMC - Type: One to One Meeting (Virtual)

- Concall Schedule - Concall Date: 30 July 2026 - Analyst/Investor: Ventura Securities Limited - Type: One to One Meeting - Mode: Virtual Meeting

- Investor Meeting Schedule - Meeting Date: 30 July 2026 - Participants: Tamohara Investment Managers Pvt. Ltd. - Mode: One to One Virtual Meeting

- Investor Meeting Schedule - Meeting Date: 28 July 2026 - Investor: Alchemy Capital Management Pvt. Ltd. - Type: One on One Meeting (Virtual)

- Strong Q1 FY27 performance: Operating Revenue INR 1,671 million (▲43% YoY) and EBITDA INR 323 million (▲86% YoY). Segment-wise, PTC, Electrolyte Salts, PASC, and SDA all showed significant YoY growth. - FY27 guidance: Expects to maintain 25-30% growth run rate and 20-22% EBITDA margins. Targets 20-25% YoY compounded growth for the next 3-4 years and 20-22% ROIC. - Capex & Expansion: Board approved INR 200 crores for a new greenfield manufacturing facility, expected to be operational within 18-21 months, targeting ~INR 300 crores revenue at peak utilization. - Key Developments: First batch of semiconductor chemical successfully qualified. Hybrid battery customer commercialization for Electrolyte Salts to begin from Oct/Nov 2026. Euro 7 implementation strengthens SDA outlook. 9 mature products (excluding semiconductor) expected to commercialize before 2028. Continuous flow chemistry is a core focus.

- Concall Schedule - Concall Date: 27 July 2026 - Meeting Details: Virtual Group Meeting hosted by ULJK Financial Services Pvt. Ltd. for analysts/financial institutions/investors.

- Groundbreaking Ceremony (Bhoomi Pujan) held for a new greenfield manufacturing unit at Dahej - III, Bharuch, Gujarat on July 20, 2026. - The new facility is part of the Company's growth strategy to strengthen infrastructure and meet growing market demands.

- Earnings Call recording held on July 17, 2026, at 05:00 p.m. IST is now available on the company's website.

- Consolidated Revenue ₹1,670.55 million vs ₹1,168.64 million (▲42.94% YoY) - EBITDA ₹350.76 million vs ₹184.85 million (▲89.76% YoY) - PAT ₹159.81 million vs ₹66.51 million (▲140.28% YoY) - EBITDA Margin 21.00% vs 15.82% (▲518bps) - Board approved capacity expansion of 344 KL reactor capacity at Dahej-III with an investment of ₹200 Crores, to be completed in 21 months. - Board approved increasing borrowing limits from ₹300 Crores to ₹1,000 Crores.

- Consolidated Revenue ₹167.06 Cr vs ₹116.86 Cr (▲42.95% YoY) - EBITDA ₹30.98 Cr vs ₹17.33 Cr (▲78.77% YoY) - PAT ₹15.98 Cr vs ₹6.65 Cr (▲140.30% YoY) - EBITDA Margin 18.54% vs 14.83% (▲371 bps) - Board approved capacity expansion of 344 kilolitres (KL) for specialty chemicals at the new greenfield unit at Dahej - III, with an investment of ₹200 Crores over approximately 21 months, to be financed by internal accruals and debt. - Re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director, and Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors for a further three years, effective February 1, 2027, subject to member approval. - Approved increasing the Company's borrowing limits from ₹300 Crores to ₹1,000 Crores, subject to approval from members at the ensuing Annual General Meeting.

- Consolidated Revenue ₹1,670.55 million vs ₹1,168.64 million (▲43.0% YoY) - EBITDA ₹309.78 million vs ₹173.30 million (▲78.8% YoY) - PAT ₹159.81 million vs ₹66.51 million (▲140.3% YoY) - EBITDA Margin 18.5% vs 14.8% (▲370bps) - Board approved proposed capacity expansion of 344 kilolitres (KL) at the new greenfield unit in Dahej - III, with an investment of ₹200 Crores and a completion timeline of approximately 21 months. - The Company's borrowing limits were increased from ₹300 Crores to ₹1,000 Crores, subject to shareholder approval. - Re-appointment of Mr. Chintan Nitinkumar Shah (Managing Director), Mr. Ajaykumar Mansukhlal Patel (Whole-time Director), and Mr. Shekhar Rasiklal Somani (Whole-time Director) for a further period of three years, effective February 1, 2027, subject to member approval.

New Filing detected. See link for details.

- The trading window for Designated Persons and their immediate relatives will close from July 01, 2026. - It will remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026.

- Concall Schedule - Concall Date: 17 June 2026 - Investor: Valcore Capital Advisors - Type: One on One Meeting - Mode: Virtual Meeting